NCT05732285 (CoINTEGRATE) is a NA clinical trial of CRT in Neurocognitive Disorders, sponsored by University of Michigan.

Who is sponsoring NCT05732285?

NCT05732285 is sponsored by University of Michigan.

What drugs are being tested in NCT05732285?

Interventions in NCT05732285: CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation.

What condition does NCT05732285 study?

NCT05732285 studies Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment.

Is NCT05732285 still recruiting?

NCT05732285 is currently completed. Last updated 20 October 2025.

Last reviewed 2025-10-20 · How we verify

NCT05732285: CoINTEGRATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Randomized Controlled Trial: CoINTEGRATE

Completed NA Last updated 20 October 2025

What this trial tests

NA trial testing CRT in Neurocognitive Disorders in 15 participants. Completed in 1 October 2025.

Timeline

1 September 2023

Primary endpoint
1 September 2025

1 October 2025

Quick facts

Lead sponsor	University of Michigan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	15
Start date	1 September 2023
Primary completion	1 September 2025
Estimated completion	1 October 2025
Sites	1 location across United States

Drugs / interventions tested

CRT
CBT — full drug profile →
Modifiable lifestyle factors
Usual care Psychoeducation

Conditions studied

Neurocognitive Disorders — all drugs for Neurocognitive Disorders →
Cognitive Dysfunction — all drugs for Cognitive Dysfunction →
Traumatic Brain Injury — all drugs for Traumatic Brain Injury →
Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

University of Michigan

Who can join

Adults 21 to 65, any sex, with Neurocognitive Disorders or Cognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions. The study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (CI) and Quality of life (QoL) in patients with a neurocognitive disorder compared to usual care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Applicability and adaptation of cognitive behavior therapy for long COVID neuropsychiatric symptoms: a review with insights from ME/CFS.
Takamatsu N, Kuga H. · · 2025 · cited 1× · PMID 41073921 · DOI 10.1186/s12879-025-11754-0

Verify or expand the search:

Other trials of CRT

Trials testing the same drug.

NCT05912036 — The CORTEX Randomized Control Trial · NA · unknown
NCT05854290 — Comprehensive Cognitive and Affective Intervention for Mild Cognitive Impairment (MCI) for Foreign-Born Arab Americans · NA · terminated
NCT05669092 — A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status · Phase 3 · unknown
NCT04564482 — PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer · NA · recruiting
NCT05428787 — Resynchronization in Patients With HF in AF Trial Undergoing Pace & AVNA Strategy With LBBAP Compared With BiV Pacing · NA · active not recruiting

Other recruiting trials for Neurocognitive Disorders

Currently open trials in the same condition.

NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
NCT06638710 — Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and · Phase 2 · recruiting
NCT07048002 — Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery · NA · recruiting

Other University of Michigan trials

Trials by the same sponsor.

NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05732285 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 20 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05732285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing